Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data PROKIDNEY CORP. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
0.08
0.89
Research and development
21
46.3
82.1
107
128
114
General and administrative
5.98
8.86
70.9
44.8
56.1
51.8
Operating expenses
27
55.1
153
152
184
166
Operating income
-27
-55.1
-153
-152
-184
-165
Interest expense
0
0
0.22
0.01
0.01
0
Pre-tax income
-27
-55.1
-147
-129
-164
-151
Income tax
-0.23
0.04
0.9
6
-0.6
0.41
Net income
-26.7
-55.1
-148
-35.5
-61.2
-69
EBITDA
-26.1
-53.1
-150
-148
-178
-158
EPS, basic
-0.23
EPS, diluted
-0.23
Shares, basic (weighted)
61.5
Shares, diluted (weighted)
61.5
Balance sheet
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
4.58
20.6
490
60.6
99.1
109
Other current assets
0.03
1.38
0.01
0.08
2.8
Total current assets
27.3
505
374
396
281
Property, plant and equipment
11.4
10.7
42.1
42.2
51.2
Lease right-of-use assets
1.14
2.29
4.12
2.87
3.59
Intangible assets
0.43
0.21
0
Total assets
40.3
518
421
441
336
Accounts payable
2.83
3.04
5.1
3.63
0.94
Accrued liabilities
9.21
7.34
17.7
31.1
28.7
Total current liabilities
12.3
10.9
25
36.2
30.7
Lease liabilities
0.99
1.86
3.51
2.39
2.91
Total liabilities
13.4
13.1
29.2
39.4
34.8
Paid-in capital
0
7.48
36.1
206
259
Retained earnings
-162
-1,104
-1,140
-1,201
-1,270
Other comprehensive income
0
0.13
0.13
0.06
Shareholders' equity
9.86
26.9
-1,097
-1,103
-995
-1,011
Total equity
9.86
26.9
-1,097
-1,103
-995
-1,011
Total liabilities and equity
40.3
518
421
441
336
Cash flow statement
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-26.7
-55.1
-148
-135
-163
-152
Depreciation and amortization
0.96
1.98
3.04
3.85
5.43
6.58
Stock-based compensation
0.73
0.7
74.5
30.8
29.4
25.3
Change in payables
0.68
7.87
0.49
11.6
11.6
-5.92
Cash from operations
-25.2
-50.3
-77.1
-90.1
-126
-120
Capital expenditures
-5.46
-5.19
-1.85
-34.2
-29.5
-15.2
Purchases of investments
0
0
-472
-324
-217
Sales and maturities of investments
0
0
176
374
318
Cash from investing
-5.46
-5.19
-1.74
-330
20.4
104
Stock issued
0
0
0
0
144
24.2
Share buybacks
0
0
-9.5
0
0
Cash from financing
20
71.5
549
-9.55
144
25.6
Net change in cash
-10.6
16
470
-430
38.5
9.42
Free cash flow
-30.6
-55.5
-78.9
-124
-156
-135
Income taxes paid
0.15
0.07
1.95
2.86
0.07
2.44
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.60 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-21,665.0%
Operating income / revenue.
EBITDA margin
-20,889.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-20,388.0%
Pre-tax income / revenue.
Net margin
-10,288.0%
Net income / revenue.
FCF margin
-19,527.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-17,258.0%
Cash from operations / revenue.
Return on assets (ROA)
-33.8%
Net income / average total assets.
R&D / revenue
16,004.0%
Research and development expense / revenue.
Stock-based pay / revenue
2,802.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
2,270.0%
Capital expenditures / revenue.
D&A / revenue
775.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
1,075.0%
Revenue vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-23.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-13.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
8.36x
Current assets / current liabilities.
Quick ratio
3.30x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.30x
(Cash + short-term investments) / current liabilities.
Market cap + total debt - cash - short-term investments.
P/S
591x
Market cap / revenue.
EV/Sales
500x
Enterprise value / revenue.
FCF yield
-33.0%
Free cash flow / market cap.
Earnings yield
-17.4%
Net income / market cap (the inverse of P/E).
What was PROKIDNEY CORP.'s revenue in fiscal 2025?
PROKIDNEY CORP. reported revenue of $893.0K for fiscal 2025, 1,075% higher than the year before.
Was PROKIDNEY CORP. profitable in fiscal 2025?
No. It reported a net loss of $69.0M.
How much free cash flow did PROKIDNEY CORP. generate in fiscal 2025?
Cash from operations of $120.1M minus capital expenditures of $15.2M left free cash flow of -$135.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.